Questions across 2 calls

Harith Ahamed

Firm not listed in source transcripts

Eris Lifesciences Limited

Eris Lifesciences Limited CC-Nov25.pdf · 2025-11-12

Hi. Good evening. Thanks for the opportunity. So, my first question is on the insulin aspart product which you mentioned is a targeted launch for the second half of FY26. So, trying to understand the status of this product fr om a regulatory standpoint, has it been filed? When are we expecting the approval? And is this an exclusive arrangement that Biocon will have with Eris for the Indian market?

Okay. And the Cartridge capacity expansion at Bhopal, what is the status there, and what are the timelines that we're looking at now?

Biocon Limited

Biocon Limited CC-Nov25.pdf · 2025-11-12

Hi, this is Harith from Spark Avendus. So, my first question is on the recent revised or updated guidance document from the FDA on the lowering requirements around comparative efficacy trials. And do we expect this to be a positive for us in terms of the R&D spends that we do on developing each biosimilar product?

And would you expect some of the newer players to accelerate their development and hence, more competitive intensity in the space?